Home >> Research Area >>Natural Products>>Diterpenoids>> ent-16beta,17-Dihydroxy-19-kauranoic acid

ent-16beta,17-Dihydroxy-19-kauranoic acid

CAS# 3301-61-9

ent-16beta,17-Dihydroxy-19-kauranoic acid

Catalog No. BCN1457----Order now to get a substantial discount!

Product Name & Size Price Stock
ent-16beta,17-Dihydroxy-19-kauranoic acid: 5mg $828 In Stock
ent-16beta,17-Dihydroxy-19-kauranoic acid: 10mg Please Inquire In Stock
ent-16beta,17-Dihydroxy-19-kauranoic acid: 20mg Please Inquire Please Inquire
ent-16beta,17-Dihydroxy-19-kauranoic acid: 50mg Please Inquire Please Inquire
ent-16beta,17-Dihydroxy-19-kauranoic acid: 100mg Please Inquire Please Inquire
ent-16beta,17-Dihydroxy-19-kauranoic acid: 200mg Please Inquire Please Inquire
ent-16beta,17-Dihydroxy-19-kauranoic acid: 500mg Please Inquire Please Inquire
ent-16beta,17-Dihydroxy-19-kauranoic acid: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of ent-16beta,17-Dihydroxy-19-kauranoic acid

Number of papers citing our products

Chemical structure

ent-16beta,17-Dihydroxy-19-kauranoic acid

3D structure

Chemical Properties of ent-16beta,17-Dihydroxy-19-kauranoic acid

Cas No. 3301-61-9 SDF Download SDF
PubChem ID 442023 Appearance Powder
Formula C20H32O4 M.Wt 336.5
Type of Compound Diterpenoids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
SMILES CC12CCCC(C1CCC34C2CCC(C3)C(C4)(CO)O)(C)C(=O)O
Standard InChIKey MRBLTWPEPGRXQN-INIPNLRTSA-N
Standard InChI InChI=1S/C20H32O4/c1-17-7-3-8-18(2,16(22)23)14(17)6-9-19-10-13(4-5-15(17)19)20(24,11-19)12-21/h13-15,21,24H,3-12H2,1-2H3,(H,22,23)/t13-,14+,15+,17-,18-,19+,20+/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of ent-16beta,17-Dihydroxy-19-kauranoic acid

The herbs of Xanthium sibiricum Patrin

Protocol of ent-16beta,17-Dihydroxy-19-kauranoic acid

Structure Identification
Journal of Chinese Pharmaceutical Sciences, 2006, 41(24):1854-1857.

Study on chemical constituents of Herba Siegesbeckiae.[Reference: WebLink]

To study the chemical constituents in the ethyl acetate fraction of Herba Siegesbeckiae.
METHODS AND RESULTS:
Compounds were isolated and purified by silica gel columns and MPLC, and their structures were identified by the physicochemical properties and spectral analysis. Seven compounds were isolated and elucidated as 3′,5′,β-trihydroxy-3,4,4′, α-tetramethoxy-chalcone (1), kirenol (2), darutigenol (3), siegesbeckic acid (4), ent-16β,17-dihydroxy-19-kauranoic acid (ent-16beta,17-Dihydroxy-19-kauranoic acid,5), ent-16αH-17- hydroxy-19-kauranoic acid (6) and stigmasterol (7).
CONCLUSIONS:
Compound 1 is the new compound.

ent-16beta,17-Dihydroxy-19-kauranoic acid Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

ent-16beta,17-Dihydroxy-19-kauranoic acid Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of ent-16beta,17-Dihydroxy-19-kauranoic acid

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.9718 mL 14.8588 mL 29.7177 mL 59.4354 mL 74.2942 mL
5 mM 0.5944 mL 2.9718 mL 5.9435 mL 11.8871 mL 14.8588 mL
10 mM 0.2972 mL 1.4859 mL 2.9718 mL 5.9435 mL 7.4294 mL
50 mM 0.0594 mL 0.2972 mL 0.5944 mL 1.1887 mL 1.4859 mL
100 mM 0.0297 mL 0.1486 mL 0.2972 mL 0.5944 mL 0.7429 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on ent-16beta,17-Dihydroxy-19-kauranoic acid

Ent-16beta,17-dihydroxy-kauran-19-oic acid, a kaurane diterpene acid from Siegesbeckia pubescens, presents antiplatelet and antithrombotic effects in rats.[Pubmed:21377851]

Phytomedicine. 2011 Jul 15;18(10):873-8.

The antiplatelet and antithrombotic effects of ent-16beta,17-dihydroxy-kauran-19-oic acid (DDKA) isolated from Siegesbeckia pubescens were investigated with different methods both in vitro and in vivo. We tested the antithrombotic activity of DDKA in arterio-venous shunt model. The effects of DDKA on adenosine diphosphate (ADP)-, Thrombin-, Arachidonic acid-induced rat platelets aggregation were tested in vitro. We also assessed its bleeding side effect by measuring coagulation parameters after intravenous administration for 5 days and investigated the potential mechanisms underlying such activities. In vivo, DDKA significantly reduced thrombus weight in the model of arterio-venous shunt. Meanwhile, DDKA increased plasma cAMP level determined by radioimmunoassay in the same model. Notably, DDKA prolonged PT and APTT in rats after intravenous administration DDKA for successive 5 days. In vitro, pretreatment with DDKA on washed rat platelets significantly inhibited various agonists stimulated platelet aggregation and caused an increase in cAMP level in platelets activated by ADP. These findings support our hypothesis that DDKA possesses antiplatelet and antithrombotic activities. The mechanisms underlying such activities may involve the anticoagulatory effect and cAMP induction.

Hydroxylation and glucosidation of ent-16beta-Hydroxybeyeran-19-oic acid by Bacillus megaterium and Aspergillus niger.[Pubmed:15095153]

Planta Med. 2004 Apr;70(4):359-63.

ent-16beta-Hydroxybeyeran-19-oic acid ( 1) has potential antihypertensive activity. To obtain novel and more-effective compounds, 1 was incubated with Bacillus megaterium ATCC 14 581 and Aspergillus niger CCRC 32 720. The structures of the metabolites were determined by HR-FAB-MS, 1D- and 2D-NMR spectral data, and enzymatic hydrolysis. Bacillus megaterium hydroxylated and glucosidated 1 to yield ent-7alpha,16beta-dihydroxybeyeran-19-oic acid ( 2), ent-16beta-hydroxybeyeran-19-oic acid alpha- D-glucopyranosyl ester ( 3), and ent-7alpha,16beta-dihydroxybeyeran-19-oic acid alpha- D-glucopyranosyl ester ( 4). Aspergillus niger hydroxylated 1 to yield ent-1beta,7alpha,16beta-trihydroxybeyeran-19-oic acid ( 5) and ent-1beta,7alpha-dihydroxy-16-oxobeyeran-19-oic acid ( 6). Metabolites 3 - 5 were characterized as new compounds. In addition, 2, 3, 5, and 6 were tested for antihypertensive effects, and we found that 5 and 6 were more potent than the parent compound 1.

Simultaneous quantification of Kirenol and ent-16beta,17-dihydroxy-kauran-19-oic acid from Herba Siegesbeckiae in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies.[Pubmed:24008120]

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Oct 15;937:18-24.

A rapid and specific liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method was developed for the simultaneous determination of two active diterpenoids: Kirenol and ent-16beta,17-dihydroxy-kauran-19-oic acid (DHKA) from Herba Siegesbeckiae in rat plasma using osthole as an internal standard (IS). Plasma sample pretreatment involved a one-step liquid-liquid extraction with ethyl acetate. Chromatographic separation was performed on a Waters Symmetry C18 column (2.1mmx100mm, 3.5mum) with isocratic elution using methanol-5mmol/L aqueous ammonium acetate (80:20, v/v) as the mobile phase at a flow rate of 0.2mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer in multiple reaction monitoring (MRM) mode under positive and negative electrospray ionization. The calibration curves were linear over the range of 50.0-25,000ng/mL for Kirenol, and 25.0-12,500ng/mL for DHKA. The extraction recoveries of the two analytes and the IS were all over 85%. The intra- and inter-day precision (relative standard deviation) values were less than 16.8% and the accuracy (relative error) ranged from -10.7 to 10.6% at four quality control levels. The validated method was successfully applied to a comparative pharmacokinetic study of the two diterpenoids in rat plasma after intragastric administration of Kirenol, DHKA and Herba Siegesbeckiae extract. The results showed that there were obvious differences between the pharmacokinetic behaviors after oral administration of Herba Siegesbeckiae extract compared with each of the substances alone.

Keywords:

ent-16beta,17-Dihydroxy-19-kauranoic acid,3301-61-9,Natural Products, buy ent-16beta,17-Dihydroxy-19-kauranoic acid , ent-16beta,17-Dihydroxy-19-kauranoic acid supplier , purchase ent-16beta,17-Dihydroxy-19-kauranoic acid , ent-16beta,17-Dihydroxy-19-kauranoic acid cost , ent-16beta,17-Dihydroxy-19-kauranoic acid manufacturer , order ent-16beta,17-Dihydroxy-19-kauranoic acid , high purity ent-16beta,17-Dihydroxy-19-kauranoic acid

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: